
    
      The rationale for Amendment 2 is 2-fold. First, it is intended that this study serve as a
      rollover protocol for patients who experience progressive disease (PD) after receiving the
      comparator treatment, high-dose dexamethasone, in MPI Study M34101-039, thereby ultimately
      providing all patients who participate in Study M34101-039 and require treatment for their
      disease access to VELCADEâ„¢ (bortezomib) for Injection, formerly known as MLN341, LDP-341 and
      PS-341.
    
  